Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease

Drugs of Today

Volumn 44, Issue 8, 2008, Pages 577-584

  Del Vecchio, Lucia ^a   Cavalli, Andrea ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; MACROGOL; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CHRONIC KIDNEY DISEASE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOASSAY; INJECTION SITE BLEEDING; PERIPHERAL EDEMA; QUALITY OF LIFE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE;

ANEMIA; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; POLYETHYLENE GLYCOLS;

EID: 56049120832     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.8.1241306     Document Type: Article

References (38)

1. Lin, F.K., Suggs, S., Lin, C.H. et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985, 82(22): 7580-4.
2. Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., Cotes, P.M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986, 2(8517): 1175-8.
3. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316(2): 73-8.
4. Storring, P.L. Tiplady, R.J., Gaines Das, R.E., Stenning, B.E., Lamikanra, A., Rafferty, B., Lee, J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998, 100(1): 79-89.
5. Powell, U.S., Berkner, K.L., Lebo, R.V., Adamson, J.W. Human erythropoietin gene: High level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA 1986, 83(17): 6465-9.
6. Nimtz, M., Martin, W., Wray, V., Kloppel, K.D., Augustin, J., Conradt, H.S. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 1993, 213(1): 39-56.
7. Deicher, R., Horl, W.H. Differentiating factors between erythropoiesis-stimulating agents: A guide to selection for anaemia of chronic kidney disease. Drugs 2004, 64(5): 499-509.
8. Kwan, J.T., Pratt, R.D.; The Epoetin Delta Study Group. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007, 23(2): 307-11.
9. Egrie, U.C., Browne, K.J. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001, 16(Suppl. 3): 3-13.
10. Macdougall, I.C., Eckardt, K.U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006, 368(9539): 947-53.
11. Brandt, M., Lazendörfer, M., Frische, J. et al. Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 2006, 21(Suppl. 4): Abst SO018.
12. Macdougall, I.C. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005, 4(6): 436-40.
13. Rastogi, A., Nissenson, A.R. New approaches to the management of anemia of chronic kidney disease: Beyond Epogen and Infed. Kidney Int 2006, 70(Suppl. 1): S14-S16.
14. Tare, N., Pill, J., Mosel, W. et al. Preclinical pharmacodynamics and pharmacokinetics of CERA (continuous erythropoiesis receptor activator): A new erythropoietic agent for anaemia management in patients with kidney disease. Nephrol Dial Transplant 2003, 18(Suppl. 4): Abst M526.
15. Reigner, B., Jordan, P., Pannier, A., Glaspy, J. Phase I studies with C.E.R.A. (continuous erythropoiesis receptor activator), an innovative erythropoietic agent. Eur J Cancer 2003, 1(Suppl. 5): Abst 568.
16. Fishbane, S., Pannier, A., Liogier, X., Jordan, P., Dougherty, F.C., Reigner, B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007,47(11): 1390-7.
17. Dougherty, F.C., Reigner, B., Jordan, P., Pannier, A. CERA (continuous erythropoiesis receptor activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies. Proc Am Soc Clin Oncol 2004, 23: Abst 6692.
18. Tsubakihara, Y., Bessho, M., Suzuki, M. Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of intravenous (IV) administrations of C.E.R.A. (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients not on dialysis. Nephrol Dial Transplant 2006, 21(Suppl. 4): Abst SP406.
19. Locatelli, F., Reigner, B. C.E.R.A.: Pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007, 16(10): 1649-61.
20. Macdougall, I.C., Robson, R., Opatrna, S. et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006, 1(6): 1211-5.
21. Kindler, J., Eckardt, K.U., Ehmer, B. et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989, 4(5): 345-9.
22. Jensen, J.D., Jensen, L.W., Madsen, J,K., Poulsen, L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995, 54(2): 111-6.
23. Walrafen, P., Verdier, F., Kadri, Z., Chretien, S., Lacombe, C., Mayeux, P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005, 105(2): 600-8.
24. Halstenson, C.E., Macres, M., Katz, S.A., Schnieders, J.R., Watanabe, M., Sobota, J.T., Abraham, P.A. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991, 50(6): 702-12.
25. Macdougall, I.C., Gray, S.J., Elston, O., Breen, C., Jenkins, B., Browne, J., Egrie, J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999, 10(11): 2392-5.
26. Dougherty, F.C., Leypoldt, U.K., Cheung, A.K., Loghman-Adham, M. No effect of hemodialysis or hemofiltration on concentrations of CERA (continuous erythropoietin receptor activator): In vitro study results. J Am Soc Nephrol 2003, 14: Abst SU-PO1065.
27. de Francisco, A.L., Sulowicz, W., Klinger, M. et al.; BA16260 Study Invesigators. Continuous erythropoietin receptor activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: A randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006, 60(12): 1687-96.
28. Provenzano, R., Besarab, A., Macdougall, I.C. et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol 2007, 67(5): 306-317.
29. Provenzano, R., Dougherty, F.C. Subcutaneous (SC) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis. Am J Kidney Dis 2006, 47: Abst 126.
30. Besarab, A., Salifu, M.O., Lunde, N.M. et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic kidney disease. Clin Ther 2007, 29(4): 626-39.
31. Locatelli, F., Villa, G., De Francisco, A.L.M. et al.; BA16286 Study Investigators Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007, 23(5): 969-79.
32. Macdougall, I.C., Walker, R., Provenzano, R. et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. J Am Soc Nephrol 2006, 17: Abst SA-PO208.
33. Klinger, M., Arias, M., Vargemezis, V. et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: A randomized trial. Am J Kidney Dis 2007, 50(6): 989-1000.
34. Canaud, B., Braun, J., Locatelli, F. et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Nephrol Dial Transplant 2006, 21(Suppl. 4): Abst SP425.
35. Levin, N.W., Fishbane, S., Canedo, F.V. et al.; MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet 2007, 370(9596): 1415-21.
36. Sulowicz, W., Locatelli, F., Ryckelynck, J.P., et al.; PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007, 2(4): 637-46.
37. Spinowitz, B., Coyne D.W., Lok, C.E., et al.; RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008, 28(2): 280-9.
38. Yang, W., Israni, R.K., Brunelli, S.M., Joffe, M.M., Fishbane, S., Feldman H.I. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007, 18(12).